NXTC — NextCure Inc
NASDAQ · Healthcare · Biotechnology
$6.93
+$0.13 (+1.91%)
NextCure Inc (NXTC) is a biotechnology company listed on NASDAQ. It is led by Michael S. Richman MSBA, based in 9000 Virginia Manor Road, Beltsville, MD, United States, 20705, with about 40 employees. NextCure, Inc., a clinical-stage biopharmaceutical company, engages in advancing medicines to treat cancer. The company's product candidate is the LNCB74, a B7-H4 targeted ADC to kill tumors. It also develops NC410, a fusion protein of LAIR-2, that is designed to block immune suppression mediated by LAIR-1; NC525, a novel LAIR-1 antibody that targets acute myeloid leukemia, blast cells, and leukemic stem cells; NC181 a humanized antibody targeting ApoE4 for the treatment of Alzheimer's disease; and NC605 an antibody that targets Siglec-15, as well as chronic bone diseases, such as osteoarthritis and non-union fractures. The company also develop SIM0505, a novel antibody-drug conjugate (ADC) targeting CDH6 (cadherin-6 or K-cadherin) for the treatment of solid tumors. The company was incorporated in 2015 and is headquartered in Beltsville, Maryland.
Net income was -$46.4M. NXTC currently screens at market cap $11.5M.
Use this NXTC page for company research — sector, financials, and the latest filing takeaway — not a live tape. The session quote (last, range, volume) lives on the NXTC quote page. Cached 10-K, 10-Q, 8-K, and Form 4 exhibits are on the NXTC SEC filings page. Lician reads the product cache first so this HTML stays unique to NextCure Inc even when a live quote feed is slow.
About NextCure Inc
NextCure, Inc., a clinical-stage biopharmaceutical company, engages in advancing medicines to treat cancer. The company's product candidate is the LNCB74, a B7-H4 targeted ADC to kill tumors. It also develops NC410, a fusion protein of LAIR-2, that is designed to block immune suppression mediated by LAIR-1; NC525, a novel LAIR-1 antibody that targets acute myeloid leukemia, blast cells, and leukemic stem cells; NC181 a humanized antibody targeting ApoE4 for the treatment of Alzheimer's disease; and NC605 an antibody that targets Siglec-15, as well as chronic bone diseases, such as osteoarthritis and non-union fractures. The company also develop SIM0505, a novel antibody-drug conjugate (ADC) targeting CDH6 (cadherin-6 or K-cadherin) for the treatment of solid tumors. The company was incorporated in 2015 and is headquartered in Beltsville, Maryland.
NXTC Key Statistics
Market Cap
$11.52M
Volume
4,174
Previous Close
$5.89
Day Range
$6.00 – $6.10
EPS
-$1.99
Revenue
$0.00
Net Income
-$55.65M
Gross Profit
$0.00
Free Cash Flow
$0.00
Employees
40
NXTC Financials
Annual income statement in USD. Latest reported periods first.
| Line | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|
| Revenue | $0.00 | $0.00 | $0.00 | $0.00 |
| Cost of Revenue | $0.00 | $0.00 | $0.00 | $0.00 |
| Gross Profit | $0.00 | $0.00 | $0.00 | $0.00 |
| Operating Income | $0.00 | $0.00 | $0.00 | $0.00 |
| Net Income | -$55.65M | -$62.72M | -$74.73M | -$69.39M |
| EPS (Diluted) | -$1.99 | -$2.25 | -$2.69 | -$2.51 |
Total Assets
$80.86M
Total Debt
$0.00
Shareholders' Equity
$0.00
Cash & Equivalents
$27.73M
Operating Cash Flow
-$40.80M
Free Cash Flow
$0.00
NextCure Inc Company Information
- Co-Founder, CEO, President & Director
- Michael S. Richman MSBA
- Headquarters
- 9000 Virginia Manor Road, Beltsville, MD, United States, 20705
- Website
- www.nextcure.com
- Phone
- 240 399 4900
- IPO / Founded
- 2019-05-09
- Sector
- Healthcare
- Industry
- Biotechnology